Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis.
Paul Michael HallerNiema KazemStefan AgewallClaudio BorghiClaudio CeconiDobromir DobrevElisabetta CerbaiErik Lerkevang GroveJuan Carlos KaskiBasil S LewisAlexander NiessnerBianca RoccaGiuseppe M C RosanoGianluigi SavareseRenate B SchnabelAnne Grete SembSamuel SossallaSven WassmannPatrick SulzgruberPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
In this comprehensive analysis of mainly observational data, the use of DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution, compared with VKA therapy. The use of DOACs was associated with a lower rate of all-cause death and fewer bleeding events. Adequately sized randomized clinical trials are needed to confirm these findings, which could allow a wider adoption of DOACs in patients with LVT.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- left atrial
- left ventricular
- venous thromboembolism
- electronic health record
- heart failure
- catheter ablation
- acute myocardial infarction
- percutaneous coronary intervention
- hypertrophic cardiomyopathy
- big data
- cardiac resynchronization therapy
- mitral valve
- aortic stenosis
- stem cells
- machine learning
- mesenchymal stem cells
- coronary artery disease
- bone marrow
- brain injury